Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Drug Interaction Potentiation: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Drug Interaction Potentiation: 1 US clinical trial tracked, none currently recruiting.

Drug Interaction Potentiation is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Vifor Pharma, running 1 of these trials.

Enrollment posture brief

Registry condition drug-interaction-potentiation

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Drug Interaction Potenti (th…0%
Open-enrollment share among volume-matched conditions near Drug Interaction Potentiation

Drug Interaction Potentiation has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Drug Interaction Potentiation on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Drug Interaction Potentiation is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Vifor Pharma 1 trials

Named interventions

Most-linked intervention names on Drug Interaction Potentiation records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PA21 Drug
1 trials
Warfarin Drug
1 trials

US sites by state

Facility locations filed on Drug Interaction Potentiation trials. A trial with sites in several states counts in each.

Kansas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Drug Interaction Potentiation page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Drug Interaction Potentiation trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Vifor Pharma sponsors the most Drug Interaction Potentiation trials on record, review their full trial history before evaluating a specific study. See Vifor Pharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Drug Interaction Potentiation condition card totals 1 registered trials; most-linked intervention PA21; top US site state Kansas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.